1297 related articles for article (PubMed ID: 11270668)
21. [Blockers of receptors for advanced glycation end products--new therapeutic possibilities].
Ptasiński A; Paczek L
Pol Arch Med Wewn; 2003 Nov; 110(5):1359-66. PubMed ID: 16737008
[No Abstract] [Full Text] [Related]
22. AGE-RAGE axis blockade in diabetic nephropathy: Current status and future directions.
Sanajou D; Ghorbani Haghjo A; Argani H; Aslani S
Eur J Pharmacol; 2018 Aug; 833():158-164. PubMed ID: 29883668
[TBL] [Abstract][Full Text] [Related]
23. The role of advanced glycation in the pathogenesis of diabetic retinopathy.
Stitt AW
Exp Mol Pathol; 2003 Aug; 75(1):95-108. PubMed ID: 12834631
[TBL] [Abstract][Full Text] [Related]
24. The AGE-receptor in the pathogenesis of diabetic complications.
Vlassara H
Diabetes Metab Res Rev; 2001; 17(6):436-43. PubMed ID: 11757079
[TBL] [Abstract][Full Text] [Related]
25. Advanced glycation end products and diabetic nephropathy: a comparative study using diabetic and normal rats with methylglyoxal-induced glycation.
Rodrigues L; Matafome P; Crisóstomo J; Santos-Silva D; Sena C; Pereira P; Seiça R
J Physiol Biochem; 2014 Mar; 70(1):173-84. PubMed ID: 24078283
[TBL] [Abstract][Full Text] [Related]
26. Role of advanced glycation end products in diabetic neuropathy.
Sugimoto K; Yasujima M; Yagihashi S
Curr Pharm Des; 2008; 14(10):953-61. PubMed ID: 18473845
[TBL] [Abstract][Full Text] [Related]
27. Relationship between levels of advanced glycation end products and their soluble receptor and adverse outcomes in adults with type 2 diabetes.
Thomas MC; Woodward M; Neal B; Li Q; Pickering R; Marre M; Williams B; Perkovic V; Cooper ME; Zoungas S; Chalmers J; Hillis GS;
Diabetes Care; 2015 Oct; 38(10):1891-7. PubMed ID: 26253728
[TBL] [Abstract][Full Text] [Related]
28. Mechanistic targeting of advanced glycation end-products in age-related diseases.
Rowan S; Bejarano E; Taylor A
Biochim Biophys Acta Mol Basis Dis; 2018 Dec; 1864(12):3631-3643. PubMed ID: 30279139
[TBL] [Abstract][Full Text] [Related]
29. Generation of autoantibodies against glycated fibrinogen: Role in diabetic nephropathy and retinopathy.
Khanam A; Alouffi S; Alyahyawi AR; Husain A; Khan S; Alharazi T; Akasha R; Khan H; Shahab U; Ahmad S
Anal Biochem; 2024 Jan; 685():115393. PubMed ID: 37977213
[TBL] [Abstract][Full Text] [Related]
30. Diabetic nephropathy and advanced glycation end products.
Menè P; Festuccia F; Polci R; Pugliese F; Cinotti GA
Contrib Nephrol; 2001; (131):22-32. PubMed ID: 11125560
[No Abstract] [Full Text] [Related]
31. Interactions between advanced glycation end-products (AGE) and their receptors in the development and progression of diabetic nephropathy - are these receptors valid therapeutic targets.
Sourris KC; Forbes JM
Curr Drug Targets; 2009 Jan; 10(1):42-50. PubMed ID: 19149535
[TBL] [Abstract][Full Text] [Related]
32. Expression of receptors for advanced glycation end-products in occlusive vascular and renal disease.
Bierhaus A; Ritz E; Nawroth PP
Nephrol Dial Transplant; 1996; 11 Suppl 5():87-90. PubMed ID: 9044315
[TBL] [Abstract][Full Text] [Related]
33. Advanced glycation end products (AGEs) on the surface of diabetic erythrocytes bind to the vessel wall via a specific receptor inducing oxidant stress in the vasculature: a link between surface-associated AGEs and diabetic complications.
Wautier JL; Wautier MP; Schmidt AM; Anderson GM; Hori O; Zoukourian C; Capron L; Chappey O; Yan SD; Brett J
Proc Natl Acad Sci U S A; 1994 Aug; 91(16):7742-6. PubMed ID: 8052654
[TBL] [Abstract][Full Text] [Related]
34. AGE in micro- and macroangiopathy.
Lapolla A; Traldi P; Fedele D
Contrib Nephrol; 2001; (131):10-21. PubMed ID: 11125555
[No Abstract] [Full Text] [Related]
35. A Perspective on the Impact of Advanced Glycation End Products in the Progression of Diabetic Nephropathy.
Khanam A; Ahmad S; Husain A
Curr Protein Pept Sci; 2023; 24(1):2-6. PubMed ID: 36366848
[TBL] [Abstract][Full Text] [Related]
36. Advanced Glycation End Products and Their Effect on Vascular Complications in Type 2 Diabetes Mellitus.
Lee J; Yun JS; Ko SH
Nutrients; 2022 Jul; 14(15):. PubMed ID: 35956261
[TBL] [Abstract][Full Text] [Related]
37. Sulforaphane inhibits advanced glycation end product-induced pericyte damage by reducing expression of receptor for advanced glycation end products.
Maeda S; Matsui T; Ojima A; Takeuchi M; Yamagishi S
Nutr Res; 2014 Sep; 34(9):807-13. PubMed ID: 25241332
[TBL] [Abstract][Full Text] [Related]
38. Recent progress in advanced glycation end products and diabetic complications.
Vlassara H
Diabetes; 1997 Sep; 46 Suppl 2():S19-25. PubMed ID: 9285494
[No Abstract] [Full Text] [Related]
39. Skin AGEs and diabetic neuropathy.
Papachristou S; Pafili K; Papanas N
BMC Endocr Disord; 2021 Feb; 21(1):28. PubMed ID: 33622304
[TBL] [Abstract][Full Text] [Related]
40. Advanced glycation: implications in tissue damage and disease.
Gasser A; Forbes JM
Protein Pept Lett; 2008; 15(4):385-91. PubMed ID: 18473952
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
